Acute Myeloid Leukemia
9 videos · last 6 months shuffled daily, then older videos newest first
▶
35:12 Thrombosomes for Severe Bleeding in Leukemia and MDS
Dr. Maro Ohanian of MD Anderson Cancer Center discusses the development of thrombosomes, a freeze-dried platelet-derived product, and a phase 2 randomised trial comparing them with standard platelets in patients with MDS and acute leukemia, for OncoDaily.
▶
19:43 Steven Knapper on a Decade of AML Clinical Trials
Professor Steven Knapper, Chief Investigator of the Cancer Research UK-funded AML18 trial across about 90 centres in the UK and Denmark, reflects on over a decade of AML trials with Cardiff University's Centre for Trials Research.
▶
26:01 How Do Clinical Trials Work?
Roswell Park's Smarter Than Cancer follows an acute myeloid leukemia drug from early research through clinical trials to FDA approval with Dr. Eunice Wang, covering who can take part and how researchers judge safety.
▶
3:11 How One AML Patient Helped Discover a Life-Saving Cancer Treatment
Paul enrolled in a tissue banking clinical trial after an AML diagnosis more than 20 years ago; his samples were among the first cancer genomes sequenced, leading to the discovery of the IDH1 mutation in AML.
▶
5:12 Ziftomenib FDA Approval for AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, discusses the FDA approval of ziftomenib for AML and trials testing it with chemotherapy in newly diagnosed and relapsed or refractory disease.
▶
45:09 Rapid Genomic Profiling for the MyeloMATCH Trial
Cecilia Yeung describes a rapid genomic characterization workflow built for the MyeloMATCH umbrella trial, which assigns AML and MDS participants to molecularly defined substudies.
▶
1:38 Key Highlights from the Phase 1 Dose Escalation Study of PRGN-3006 UltraCAR-T Presented At
Dr. David A. Sallman of Moffitt Cancer Center discusses highlights from the Phase 1/1b safety study of PRGN-3006 UltraCAR-T in relapsed or refractory CD33-positive acute myeloid leukemia and higher-risk myelodysplastic syndromes.
▶
13:33 Moleculin CEO on Annamycin Trial Data in AML and Sarcoma
Moleculin CEO Walter Klemp discusses 2023 year-end preliminary data from Annamycin clinical trials in acute myeloid leukemia and soft tissue sarcoma lung metastases.
▶
6:09 Annamycin: A Next-Generation Anthracycline
Moleculin Biotech on Annamycin, a next-generation anthracycline in trials for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.